In contrast, PRI-724, a second generation β-catenin/CBP antagonist has recently completed Phase Ia clinical evaluation and has proven to be extremely safe in humans [46] and therefore in principle could be readily administered therapeutically post-myocardial infarction. Here, CREBBP is linked to myocardial infarction.